Zhehai Wang

6.7k total citations · 1 hit paper
81 papers, 1.7k citations indexed

About

Zhehai Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Zhehai Wang has authored 81 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Zhehai Wang's work include Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (27 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Zhehai Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (27 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Zhehai Wang collaborates with scholars based in China, United Kingdom and United States. Zhehai Wang's co-authors include Huan Shi, Ying Cheng, Jun Guo, Lin Liu, Shukui Qin, Yuxian Bai, Jianping Xiong, Liwei Wang, Jianming Xu and Nong Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Zhehai Wang

81 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

2013 417 citations Nong Xu, Zhehai Wang et al. Journal of Clinical Oncology profile →

Peers

Zhehai Wang

ONCOL

PRM

SURGE

Natsuko Okita Japan

Roberto Pazo-Cid Spain

Giovanni Fucà Italy

Nozomu Fuse Japan

Yoichi Naito Japan

Allyson J. Ocean United States

Yihebali Chi China

Ірина Давиденко United States

Andrea De Giglio Italy

Natsuko Okita Japan

Zhehai Wang

855 ×0.8

ONCOL

518 ×0.6

PRM

278 ×0.6

271 ×1.2

SURGE

135 ×0.7

Citations per year, relative to Zhehai Wang Zhehai Wang (= 1×) peers Natsuko Okita

Countries citing papers authored by Zhehai Wang

Since Specialization

Citations

This map shows the geographic impact of Zhehai Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhehai Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhehai Wang more than expected).

Fields of papers citing papers by Zhehai Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhehai Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhehai Wang. The network helps show where Zhehai Wang may publish in the future.

Co-authorship network of co-authors of Zhehai Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhehai Wang. A scholar is included among the top collaborators of Zhehai Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhehai Wang. Zhehai Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jie, Zhehai Wang, Yao Yu, et al.. (2024). Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8604–8604. 5 indexed citations

Guo, Jun, et al.. (2024). Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. Journal of Cancer Research and Clinical Oncology. 150(2). 42–42. 5 indexed citations

Han, Xiao, Yong Huang, Xue Meng, et al.. (2024). Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial. Signal Transduction and Targeted Therapy. 9(1). 241–241. 13 indexed citations

Guo, Jun, Li Kong, Yong Huang, et al.. (2023). Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population. Frontiers in Oncology. 12. 1070761–1070761. 10 indexed citations

Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations

Song, Xinyu, Anwen Xiong, Fengying Wu, et al.. (2023). Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. Journal for ImmunoTherapy of Cancer. 11(2). e006234–e006234. 40 indexed citations

Zhang, Li, Zhehai Wang, Jian Fang, et al.. (2022). Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 171. 56–60. 39 indexed citations

Lü, Shun, Xiaorong Dong, Hong Jian, et al.. (2021). Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. Journal of Clinical Oncology. 39(15_suppl). 9013–9013. 22 indexed citations

Cheng, Ying, Baohui Han, Kai Li, et al.. (2020). Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Cancer Medicine. 9(8). 2621–2630. 21 indexed citations

10.

Liu, Mengyao, Yuan Wang, Jun Guo, et al.. (2018). Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. OncoTargets and Therapy. Volume 11. 375–381. 9 indexed citations

11.

Song, Xinyu & Zhehai Wang. (2017). Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. OncoTargets and Therapy. Volume 10. 3119–3122. 5 indexed citations

12.

Wang, Zhehai, Yuan Wang, Qianqian Zhang, et al.. (2016). Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. Drug Design Development and Therapy. Volume 10. 2129–2136. 9 indexed citations

13.

Wang, Yuan, Qianqian Zhang, Ninghan Tang, et al.. (2016). Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Design Development and Therapy. 10. 1961–1961. 40 indexed citations

14.

Shi, Huan, Meili Sun, Lin Liu, & Zhehai Wang. (2014). Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Molecular Cancer. 13(1). 219–219. 38 indexed citations

15.

Shi, Huan, Lin Liu, & Zhehai Wang. (2012). Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Letters. 328(2). 191–197. 37 indexed citations

16.

Wang, Zhehai. (2010). Effects of metabolic enzyme CYP1A1 and GSTM1 gene polymorphisms and smoking factors on the occurrence of male lung squamous cell carcinoma. 3 indexed citations

17.

Liu, Jie, Bao Song, Zhehai Wang, et al.. (2009). DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population. Cancer Genetics and Cytogenetics. 191(2). 67–72. 21 indexed citations

18.

Wang, Zhehai. (2008). Relationship between susceptibility to lung cancer and genetic polymorphism in CYP1A1 and GSTM1. Shandong yiyao. 5 indexed citations

19.

Dong, Mei, Feng-yi Feng, Yang Zhang, et al.. (2008). [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].. PubMed. 30(3). 215–20. 4 indexed citations

20.

Wang, Zhehai, et al.. (2007). Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer. Zhongliu fangzhi yanjiu. 34(11). 845–847. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact